Skip to main content

Advertisement

Table 3 Number and proportions of patients with OI ≥ 2-fold increase at week 5 in PCV-13 serotypes by subgroup

From: Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy

  Serotype 4 Serotype 6B Serotype 14 Serotype 23F
Overall baricitinib group (N = 106) 74 (76) 76 (76) 47 (47) 73 (73)
Concomitant corticosteroids
 Yes (N = 31) 27 (87) 26 (84) 14 (45) 20 (65)
 No (N = 72) 47 (70) 50 (72) 33 (48) 53 (77)
Age group
 Patients < 65 years (N = 80) 61 (81) 66 (86) 40 (52) 58 (75)
 Patients ≥ 65 years (N = 23) 13 (57) 10 (43) 7 (30) 15 (65)
SDAI prior to vaccination
 ≤ 3.3 (N = 21) 14 (70) 16 (76) 11 (52) 16 (76)
 > 3.3 and ≤ 11 (N = 47) 36 (82) 34 (76) 24 (53) 29 (64)
 > 11 (N = 32) 23 (74) 25 (81) 11 (35) 26 (84)
Dose
 2 mg (N = 16) 11 (73) 11 (73) 9 (60) 9 (60)
 4 mg (N = 87) 63 (76) 65 (76) 38 (45) 64 (75)
  1. Data are reported as n (%)
  2. OI opsonization index, PCV-13 13-serotype pneumococcal conjugate vaccine, SDAI Simple Disease Activity Index